Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study.
Ahmet BiliciOmer Fatih OlmezMuhammed Ali KaplanBerna OksuzogluAhmet SezerNuri KaradurmusErdem CubukcuMehmet Ali Nahit SendurSercan AksoyDilek ErdemGul BasaranBurcu ÇakarAbdallah T M ShbairCagatay ArslanAhmet Taner SumbulSema Sezgin GoksuIbrahim KaradagIrfan CicinMahmut GümüşFatih SelcukbiricikHakan HarputluogluUmut DemirciPublished in: Acta oncologica (Stockholm, Sweden) (2023)
This real-life study indicates that adding P to NCT-H enables higher pCR than NCT-H in HER2+ BC, while pCR was associated with lower relapse and better EFS time.